According to recent studies adalimumab, which is an anti-TNF-α agent, has shown efficacy in treating refractory uveitis in multiple settings, including juvenile idiopathic arthritis.100–103 With regard to the treatment of glaucoma patients are initiated on antiglaucoma medications, but in complicated and severe cases surgical treatment (e.g., trabeculectomy or tube shunt surgeries) may be unavoidable. The gene discussed is TNF; the disease is uveitis.